SOPHiA GENETICS (NASDAQ:SOPH) Announces Earnings Results

SOPHiA GENETICS (NASDAQ:SOPH) released its quarterly earnings data on Tuesday. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04), Zacks reports. The firm had revenue of $24.27 million for the quarter, compared to the consensus estimate of $24.03 million. SOPHiA GENETICS had a negative net margin of 89.18% and a negative return on equity of 134.05%.

Here are the key takeaways from SOPHiA GENETICS’s conference call:

• Q3 revenue increased 25% year over year to $24.3 million, with platform analyses up 19% to a record 118,000. U.S. revenue grew 41%, while North America, Asia Pacific, and several European markets also delivered strong gains.
• Liquid biopsy analyses more than doubled year over year and rose 41% sequentially to 4,200, supported by more than 85 signed institutions. The company is adding medical-affairs resources to accelerate adoption and reimbursement efforts outside the U.S.
• Biopharma momentum continued with a new collaboration with a top-10 pharmaceutical company to develop an AI predictor for bladder-cancer immunotherapy response, building on two AstraZeneca companion-diagnostic programs. Management said biopharma is becoming an accelerator of future growth.
• Adjusted EBITDA loss improved 31% year over year to $6.1 million, with nearly 60% of incremental revenue converting to the bottom line. Management reaffirmed its expectation to reach positive adjusted EBITDA in the second half of 2027 and maintained its $29 million-$32 million full-year 2026 adjusted EBITDA loss outlook.
• The company expects 2026 revenue at the upper end of its $94 million-$96 million guidance range, although foreign-exchange movements are a reported-revenue headwind. A substantial implementation backlog provides visibility into 2027, but management acknowledged that converting signed customers to revenue more quickly remains a priority.

SOPHiA GENETICS Stock Performance

SOPH traded down $0.46 during midday trading on Thursday, hitting $6.51. 144,393 shares of the company traded hands, compared to its average volume of 337,762. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $546.04 million, a PE ratio of -5.91 and a beta of 1.09. The company’s 50-day moving average is $7.78 and its 200 day moving average is $5.98. SOPHiA GENETICS has a 52 week low of $3.83 and a 52 week high of $8.98.

Insider Activity

In other news, insider Well Van sold 6,168 shares of SOPHiA GENETICS stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $8.12, for a total value of $50,084.16. Following the completion of the sale, the insider directly owned 332,716 shares in the company, valued at $2,701,653.92. The trade was a 1.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Manuela Valente sold 4,240 shares of the business’s stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $8.13, for a total transaction of $34,471.20. Following the transaction, the insider directly owned 206,210 shares of the company’s stock, valued at $1,676,487.30. The trade was a 2.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 212,662 shares of company stock worth $1,679,149. 4.88% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research analysts have recently issued reports on SOPH shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Thursday, October 15th. HC Wainwright reissued a “buy” rating and set a $14.00 price target on shares of SOPHiA GENETICS in a research report on Monday, October 12th. BTIG Research boosted their price objective on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Finally, Zacks Research raised SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, SOPHiA GENETICS has an average rating of “Hold” and an average price target of $10.00.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a healthcare technology company that develops data-driven solutions for genomic medicine. Its cloud-based platform uses artificial intelligence, machine learning and advanced analytics to help healthcare organizations analyze and interpret complex biological and clinical data.

The company’s primary offering, the SOPHiA DDM platform, supports next-generation sequencing workflows, including data management, quality control, genomic analysis, variant interpretation and reporting.